Baxter Healthcare Sa

Nicox S.a.

Marinomed Biotech Ag

Nanotherapeutics, Inc.

Visufarma B.v.

Sabine Nakowitsch

Andreas Grassauer

Markus Wolschek

Andrej Egorov

Eva Prieschl-Grassauer

Julia Romanova

Angelika Bodenteich

Martina Morokutti-Kurz

Brigitte Krenn

Christiane Koller

Frederic Pilotaz

Marielle König-Schuster

Cornelia Kaintz

Frédéric Pilotaz

Marielle KÖNIG-Schuster

Martina Morokutti-kurz

Eva Prieschl-grassauer

Marielle Konig-Schuster

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, andextract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs

The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.

Composition effective against viral conjunctivitis

The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.

Method for production of pH stable enveloped viruses

Growing community of inventors

Vienna, Austria

Sabine Nakowitsch